Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension.
In: American Journal of Hypertension, Jg. 36 (2023-10-01), Heft 10, S. 561-567
academicJournal
Zugriff:
BACKGROUND Allisartan isoproxil is a selective nonpeptide angiotensin II (AT1) receptor blocker developed by China, this study aimed to assess its clinical efficacy for essential hypertension (EH). METHODS Patients with mild-to-moderate EH, selected at 44 sites in China from September 9, 2016, to December 7, 2018, were administered 240 mg allisartan isoproxil daily for 4 weeks. Patients with controlled blood pressure (BP) continued monotherapy for 8 weeks, others were randomly assigned (1:1) to A + D group (allisartan isoproxil 240 mg + indapamide 1.5 mg) or A + C group (allisartan isoproxil + amlodipine besylate 5 mg) for 8 weeks. BP were measured at week 4, 8 and 12. RESULTS 2,126 patients were included in the analysis. After 12 weeks of treatment, systolic blood pressure (SBP) and diastolic blood pressure (DBP) decreased by 19.24 ± 12.02 and 10.63 ± 8.89 mm Hg, respectively, and the overall BP control rate was 78.56%. The sitting blood pressures (SBP/DBP) decreased by 19.12 ± 11.71/10.84 ± 8.73 mm Hg in patients with 12 weeks allisartan isoproxil monotherapy (both P < 0.0001). The BP reductions and control rates were comparable between A + D and A + C groups. 48 patients with monotherapy-controlled BP underwent ambulatory BP monitoring, with a mean decrease in ambulatory BP of 10.04 ± 10.87/5.50 ± 8.07 mm Hg after 12 weeks of treatment, and consistent reductions between day and night. SBP and DBP had trough-to-peak ratios of 64.64% and 62.63% and smoothness indices of 3.82 and 2.92, respectively. CONCLUSIONS An allisartan isoproxil-based antihypertensive regimen can effectively control BP in patients with mild-to-moderate EH. PROJECT REGISTRATION NO CTR20160138 (Registration and Information Disclosure Platform for China Drug Clinical Studies, http://www.chinadrugtrials.org.cn/index.html). [ABSTRACT FROM AUTHOR]
Copyright of American Journal of Hypertension is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension.
|
---|---|
Autor/in / Beteiligte Person: | Wang, Hongyi ; Xi, Yang ; Chen, Yuanyuan ; Wang, Luyan ; Yang, Fan ; Lu, Xining ; Sun, Ningling |
Zeitschrift: | American Journal of Hypertension, Jg. 36 (2023-10-01), Heft 10, S. 561-567 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 0895-7061 (print) |
DOI: | 10.1093/ajh/hpad055 |
Schlagwort: |
|
Sonstiges: |
|